

Role of proton MR-spectroscopy in predicting the response of locally advanced breast cancer to neoadjuvant chemotherapy

Essay

submitted for partial fulfillment of MSC degree

In

Radiodiagnosis

By

Noha Mahfouz Salman Mokble

M.B.B.CH, Faculty of Medicine ,Cairo University

Under supervision of

Dr/Naglaa Mohamed Abdel Razeq

Assist. Professor of Radiology, Cairo University

Dr/ Omar Yousef Zakaria

Assist. Professor of Surgery, National Institute of Cancer

Dr/Sahar Mahmoud Mansour

Lecturer of Radiology, Cairo University

Cairo University

2010

Acknowledgement

First of all I am deeply thankful to GOD by the grace of whom this work was possible.

Words could not express the feeling of gratitude and respect to **Dr. Naglaa Mohamed Abdel Razek**, assist. professor of Radiology, Faculty of Medicine, Cairo University for her guidance, helpful advice and constructive supervision of this work.

Also, my deep thanks to **Dr. Sahar Mahmoud Mansour**, lecturer of Radiology, Faculty of Medicine, Cairo University for her great help and guidance during this work.

I would like to thank **Dr. Omar Yousef Zakaria**, assist. professor of Surgery, National Cancer Institute-Cairo University for his true concern, and encouragement.

It is my pleasure to express my deep appreciation to my professors, my colleagues and each member in the Radiology department, Cairo University,

My especial thanks and deep appreciation to every member of my family for their help, guidance and unlimited kind support.

Abstract

Most patients with locally advanced breast cancer(LABC) will require a modified radical mastectomy, a procedure that remains the standard surgical treatment for operable locally advanced disease.

Less extensive surgeries are being increasingly explored with the use of neoadjuvant chemotherapy (NACT). The down-staging of tumors seen in these cases not only makes them operable but also, on many occasions can be considered for breast conservative therapy (BCT).

Neoadjuvant chemotherapy, is performed prior to breast cancer surgery and offers several advantages over standard postoperative chemotherapy. It is important to know early; if the drug chosen will be effective or not.

Recently hydrogen 1 (H1) MR spectroscopy is used to detect and monitor breast cancer through measuring tCho concentration and so predicting response to chemotherapy as early as 24 hours .

Key words : magnetic resonance spectroscopy (MRS)- predict response – locally advanced breast cancer- neoadjuvant chemotherapy

Index of contents

SUBJECT	PAGE
I. Introduction and aim of work	1
II. Review of literature	
1. Anatomy	4
2. Pathology of Breast Cancer	10
3. Staging and Management of Breast Cancer	33
4. MRI of the Breast Cancer	51
5. Magnetic Resonance Spectroscopy and Response to Neoadjuvant Chemotherapy	83
III. Case Presentation	104
IV. Summary and Conclusion	113
V. References	116

List of Figures

Figures No.	subject	P.
Figure 1	external view of the breast shows; its different parts and extensions(Moore et. al.,2006)	4
Figure 2	sagittal section in the breast revealed the arrangement of breast structures. (Tank , 2005)	5
Figure 3	arterial supply and venous drainage of breast (Moore et. al. ,2006)	7
Figure 4	lymphatic drainage of the breast (Moore et. al.,2006)	8
Figure 5(a,b)	a.Gross specimen showing a ductal carcinoma of the comedo type. b.Specimen showing comedones coming out of the cut surface . (Gourtsoyannis and Ros ,2005)	15
Figure 6 a	Mammogram reveals multiple clusters of small, irregular calcifications in a segmental distribution. (Suzan ,2005)	16
Figure 6 b	Comedo DCIS fills several adjacent ducts. This type of DCIS is most frequently detected as radiologic calcifications. (Suzan,2005)	16
Figure 7a	Noncomedo DCIS. Cribriform DCIS comprises cells forming round, regular ("cookie cutter") spaces often filled with calcifying secretory material. (Suzan,2005)	17
Figure 7b	Noncomedo DCIS. This solid DCIS has almost completely filled and distorted this lobule with only a few remaining luminal cells visible. (Suzan,2005)	17

Figure 8 a	Intracystic carcinoma of the breast. The papillary configuration of the tumor is already grossly evident.(Rosai , 2006)	17
Figure 8 b	Noncomedo DCIS. Papillary DCIS. (Suzan,2005)	17
Figure 9	Lobular carcinoma in situ. Microscopic image.(Suzan,2005)	18
Figure 10	Invasive ductal carcinoma. Gross image. (Suzan,2005)	19
Figure 11 a	Invasive lobular carcinoma, Gross image. (Meenakshi , MD, Stony Brook University Medical Center).	21
Figure 11 b	Invasive lobular carcinoma. Microscopic image (Suzan,2005)	21
Figure 12 a	Medullary carcinoma, gross specimen. (Rosen,2001)	22
Figure 12 b	Medullary carcinoma. Microscopic image(Suzan,2005)	22
Figure 13 a	Mucinous (colloid) carcinoma. Microscopic image. (Suzan, 2005)	23
Figure 13 b	Mucinous carcinoma ,gross appearance. (Rosen ,2001)	23
Figure 14 (a ,b)	Tubular carcinoma.Gross and microscopic images. (Rovere et.al.,2006)	24
Figure 15(a,b)	Adenoid cystic carcinoma, cystic. Gross images (Rosen ,2001)	25
Figure 16	Adenoid cystic carcinoma. Microscopic image.(Rosen,2001)	26
Figure 17	Paget's disease. Microscopic image. (Rosen ,2001)	27
Figure 18 (a,b)	Papillary carcinoma .Gross and microscopic images.(Rosen ,2001)	28

Figure 19(a,b)	Apocrine carcinoma, Gross and microscopic images. (Rosen ,2001)	29
Figure 20	Invasive carcinoma with a cribriform growth pattern. (Rosen ,2001)	30
Figure 21	Therapeutic approach for patients with locally advanced breast cancer. (Piccart et.al.,2006)	44
Figure 22	T1-weighted non-fat saturated breast images.(Hendrick , 2008)	54
Figure23(a&b)	On MRI this cyst had a characteristically low signal intensity (black) on this T1-weighted image (a) and a high signal intensity (white) on the T2-weighted image (b).(Kopans,2007)	55
Figure 24	Axial MR image obtained with a short inversion time inversion recovery sequence(STIR) shows several areas of uniform high signal intensity in the breast, a finding that signifies one or more cysts. (Rausch and Hendrick,2006)	55
Figure 25 (A,B,C,D)	T1W gradient-echo imaging of an enhancing invasive ductal carcinoma. (A) Single slice of the pre-contrast (B) Same slice location in the first post-contrast series, immediately after injection. (C) Subtracted image of (B) minus (A). (D) Maximum intensity projection of all subtracted images showing a second cancer in the same breast.(Hendrick , 2008)	57
Figure 26	Fat suppression makes enhancing lesions easier to appreciate. (a) Fat has low signal intensity on this fat-saturated T1-weighted image prior to the IV administration of contrast. (b)The cancer in the left breast is more evident on the first fat-saturated set of images following contrast injection.(Kopans ,2007)	58
Figure 27 (a&b)	Effect of section thickness on tissue visibility and image quality. (Rausch and Hendrick,2006)	59

Figure 28 (a,b&c)	Fat suppression by means of image subtraction. (a, b) Sagittal T1-weighted breast MR images acquired before (a) and after (b) contrast agent injection and without a fat-saturation pulse.(c)Subtraction image of the same section as in a and b demonstrates an enhanced mass and several artifacts that mimic areas of contrast agent uptake. (Rauschand Hendrick,2006)	61
Figure 29	Mis-registraion artifact; (a) Pre-contrast slices acquired using T1W gradient-echo where the applied fat-saturation failed. (b) The same slice as in a of post-contrast T1W gradient echo slices.(c) Subtracted image of pre-contrast from post-contrast scan showing; mis-regitration artifact .(Hendrick ,2008)	62
Figure 30 (a&b)	The lesion is more evident on this maximum intensity (MIP) 3D display in contrast subtraction (a) single-slice subtraction image. (b) (Kopans,2007)	63
Figure 31 (a.b&c)	The 3D maximum intensity subtraction image provides an overview of the MRI information. (a) produced after the pre- and post-gadolinium images have been subtracted (b). The finest detail is seen on the individual slices, of which (c) is representative. (Kopans,2007)	64
Figure 32 (a,b&c)	Grade III inflammatory ductal breast cancer.(a)DCE-MRI source data image (b) DCE-MRI data post-processed using Functool (GE Medical systems, Milwaukee, WI, USA)and the positive enhancement integral map shows rapid and intense contrast uptake by tumour (shown as the region in red) compared with poorly enhancing normal surrounding tissue.(c)A typical pattern of contrast uptake by tumour (type 3 curve) (Turnbull,2009)	65

Figure 33	Different phases of the signal time course of a dynamic series and the respective kinetic criteria. Three phases are distinguished: (1) initial post-contrast phase (injection of contrast agent until the second post-contrast minute), (2) post initial phase (second through third post-contrast minute), (3) late post-contrast phase . (Morris and Liberman , 2005)	68
Figure 34 (a&b)	(a) Invasive ductal carcinoma on the 2D post-contrast subtraction image.(Kopans ,2007) (b) Invasive ductal carcinoma in ;Sagittal contrast-enhanced delayed T1-weighted images.(Shah et.al.,2010)	70
Figure 35	Invasive ductal carcinoma in ;Sagittal T2-weighted image shows a low signal spiculated mass. (Shah et.al.,2010)	70
Figure 36 (a&b)	Invasive ductal vs. invasive lobular carcinoma images. (Shah et.al.,2010)	71
Figure 37 (a,b&c)	A medullary carcinoma in a 44-year-old woman. MRI images (Uematsu and Kasami,2009)	73
Figure 38	A mucinous carcinoma in a 42-year-old woman. MRI images(Uematsu and Kasami,2009)	75
Figure 39(a&b)	A 36-year-old woman with inflammatory carcinoma (invasive ductal, G3) in the left breast.MRI images(Renz et.al.,2008)	77
Figure 40(a&b)	A 78-year-old woman with inflammatory carcinoma in the left breast (invasive ductal, G3). MRI images(Renz et.al.,2008)	77
Figure 41	A 35-year-old woman with dense breasts and a positive cytology for breast cancer of a 2-cm palpable lesion in the upper outer quadrant. Reformatted maximum projection images. (Kinkel and Vlastos,2001)	79

Figure 42	Depending on the dominant morphological features, lesions can be separated into focus/foci, mass, and nonmass-like enhancements. (Agrawal et.al.,2009)	80
Figure 43	The descriptor for the enhancement kinetics is based on 2 different phases: the initial phase and the delayed phase. (Agrawal et.al.,2009)	81
Figure 44 (a,b,c&d)	Effect of manual versus automated shimming for optimizing the water signal (Stanwell. and Mountford ,2007)	86
Figure 45	Single-voxel spectra,acquired at 3.0 T by using the PRESS sequence, from an apparently healthy volunteer. (Stanwell . and Mountford ,2007)	88
Figure 46	The sagittal image on the left indicates the location of an acquisition array positioned within an area of breast cancer. The figure on the right shows an array of spectra from SI, acquired at 1.5 T by using the PRESS sequence (Stanwell and Mountford ,2007)	90
Figure 47	Flow scheme for processing of a raw timedomain data file from MR spectroscopy. (Stanwell and Mountford ,2007)	94
Figure 48 (a,b,c&d)	41-year-old woman with presumably normal right breast. Single-voxel proton MR spectroscopy was then performed (Wang et al., 2008)	100
Figure 49	The axial T2-weighted image on the left indicates the voxel placement within the glandular tissue in a healthy volunteer. (Stanwell and Mountford, 2007)	101

Figure 50	MRS application in the diagnosis of breast cancer. (Stanwell and Mountford, 2007)	102
Figure 51	Maximum intensity projection MR images (left) and corresponding MR spectra (right) from 40-year-old patient (patient 12) who achieved pCR. Before and after treatment.(Baek et. al.,2009)	105
Figure 52	Maximum intensity projection MR images of 29-year-old woman who had residual invasive cancer after completing NAC. Before and after treatment. (Baek et. al.2009)	106
Figure 53	Sagittal three-dimensional gadolinium-enhanced fat-suppressed FLASH MR images (left) and corresponding spectra (right) of the right breast in a 43-year-old objective responder with invasive ductal carcinoma and positive lymph nodes. (Meisamy et. al. ,2004)	107
Figure 54	Sagittal three-dimensional gadolinium-enhanced fat-suppressed FLASH MR images (left) and corresponding spectra (right) of the right breast in a 42-year-old nonresponder with invasive ductal carcinoma. (Meisamy et. al. ,2004)	108
Figure 55	A 33-year-old young woman with locally advanced breast cancer who underwent neo-adjuvant chemotherapy after one cycle of AC. The lesion size was apparently smaller, showing 20% reduction (3.2 cm) in the superior–inferior direction. A tCho peak is also visible at 3.22 ppm .The change of tCho level showed 68% reduction after one cycle of AC.(Baek et.al ,2008)	109

List Of Tables

Table	Description	P.
1.	According to AJCC Cancer Staging Manual, Sixth Edition (2002) Tumor, Node, Metastasis (TNM) Staging Scheme for Breast Carcinoma.	35&36
2.	AJCC stage groupings; sixth edition (2002)	37
3.	Potential advantages and disadvantages of primary systemic therapy	47
4.	<i>ACR BI-RADS®–MRI Lexicon Classification</i>	82

A

AC	Anthracyclin
ACR	American Joint Committee on Cancer
ADC	Apparent Diffusion Coefficient
AJCC	American College of Radiology
ALND	Axillary lymph node dissection

B

BCT	Breast Conservative Therapy
BCS	Breast-Conserving Surgery
BMRI	Breast Magnetic resonant Imaging
BI-RADS	Breast Imaging Reporting And Data System
BRCA1	is a human caretaker gene that produces a protein called breast cancer type 1 susceptibility protein
BRCA2	is a human caretaker gene that produces a protein called breast cancer type 2 susceptibility protein
B0	Main Magnetic Field

C

CAD	Computer-Aided Detection
CE-BMRI	Contrast- Enhanced Breast Magnetic Resonance Imaging
CHESS	Chemical Shift Selective Saturation
CMF	Cyclophosphamide, Methotrexate, And 5-Fluorouracil Chemotherapy
CSI	Chemical-Shift Imaging
CT	Computed Tomography
CTX	Chemotherapy
CXR	Chest Radiograph

D

2D

Two- Dimensional

3D

Three – Dimensional

DCE-MRI

Dynamic Contrast-Enhanced Magnetic Resonance Imaging

DCIS

Ductal Carcinoma In Situ

3DFT

3D Fourier Transform

2DFT

2D Fourier Transform

E

EBCTCG

Early Breast Cancer Trialists' Collaborative Group

ER

Estrogen Receptor

F

FLASH

Fast Low-Angle Shot

FID

Free Induction Decay

FSE

Fast Spin Echo

G

Gd-DTPA

Gadolinium-DiethyleneTriaminePentaacetic Acid

GPC

Glycerophosphocholine

GRCC

Glycogen-Rich Clear Cell Carcinoma

H

¹H

Proton

H&E

Hematoxylin and Eosin Stain

HER2-

human epidermal growth factor receptor 2-Negative

¹H MR

Proton Magnetic resonance

HR+

Endocrine Receptor–Positive

I

IAC	Invasive Apocrine Carcinoma
IBTR	Ipsilateral Breast Tumor Recurrence
IBC	Inflammatory breast cancer
IDC	invasive ductal carcinoma
ILC	invasive lobular cancer

L

LABC	Locally Advanced Breast Cancer
LCIS	Lobular Carcinoma In Situ
LR	Local Recurrence

M

M	Distant Metastasis
MCA	Mucinous Cystadenocarcinoma
MIP	Maximum intensity projection
MR	Magnetic Resonance
MRI	Magnetic Resonance Imaging
MRS	Magnetic Resonance Spectroscopy
MS	Mammography Screening

N

NACT/NAC	Neoadjuvant Chemotherapy
NOS	Invasive Duct Carcinoma Not Otherwise Specified